IBRNiShares Neuroscience and Healthcare ETF
Tracks the investment results of the NYSE FactSet Global Neuro Biopharma and MedTech Index.
By iShares · Launched 2022
Annual Cost
0.47%
#2,373 of 5,861 · average
Fund Size
$6M
#5,148 of 5,861 · small
Return (1Y)Goal
+58.3%
Track Record
3 years
#2,695 of 5,861 · seasoned
Performance
Total-return NAV · USDGrowth of $10,000
$15,839+58.4%
Total-return NAV, USD. Net of fund fees, before tax.
What's inside
How Beacon categorizes this fundAsset class
EquityRegion
GlobalCap
Multi cap
Strategy
Index tracking
Sector
Health careFocus
Medical Devices
Index tracked
NYSE FactSet Global Neuro Biopharma and MedTech Index
What it actually holds
By weightConcentration
Top 10 holdings = 45.4% of fundmoderately concentrated
BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares
8.6%
Xenon Pharmaceuticals Inc
4.8%
AXSOME THERAPEUTICS, INC.
4.6%
ARROWHEAD PHARMACEUTICALS, INC.
4.4%
ALKERMES PUBLIC LIMITED COMPANY
4.2%
CENTESSA PHARMACEUTICALS PLC
4.0%
argenx SE
3.9%
PTC THERAPEUTICS, INC.
3.7%
NEUROCRINE BIOSCIENCES, INC.
3.7%
BIOGEN INC.
3.7%
Asset allocation
Stocks
99.9%
Cash
0.1%
By sector
Healthcare
100.0%
Risk profile
Last 12 months · Sharpe & Sortino need 3+ yearsVolatility (1Y)
25.6%High
Year-on-year price swings
Max drawdown
-35.4%Severe
Worst peak-to-trough loss
Sharpe (3Y)
0.55Decent risk-adjusted returns
Sortino (3Y)
0.80Moderate downside risk
Listing
- Exchange
- NYSE Arca
Full fund details
- Objective
- Tracks the investment results of the NYSE FactSet Global Neuro Biopharma and MedTech Index.
- Strategy
- Invests primarily in equity securities of U.S. and non-U.S. companies involved in neurology biopharmaceuticals and neurological devices. The Fund seeks to track the NYSE FactSet Global Neuro Biopharma and MedTech Index, which includes large-, mid-, and small-cap companies across various countries.
- Inception date
- August 24, 2022
- Fund family
- iShares
Similar funds
Same asset class, closest by strategy & exposureWhat's next?
You've looked at IBRN. Save it to your watchlist to weigh it against other funds, then turn your shortlist into a portfolio.
Data updated on 2026-08-04